NervGen Pharma Corp.
NGENF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16 | $8 | $17 | $7 |
| G&A Expenses | $9 | $10 | $6 | $6 |
| SG&A Expenses | $9 | $10 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $18 | $23 | $13 |
| Operating Income | -$25 | -$18 | -$23 | -$13 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | -$5 | $2 | $0 |
| Pre-Tax Income | -$24 | -$22 | -$21 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$22 | -$21 | -$13 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.38 | -0.39 | -0.32 |
| % Growth | 5.3% | 2.6% | -21.9% | – |
| EPS Diluted | -0.36 | -0.38 | -0.39 | -0.32 |
| Weighted Avg Shares Out | 67 | 59 | 53 | 39 |
| Weighted Avg Shares Out Dil | 67 | 59 | 53 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$18 | -$23 | -$13 |
| % Margin | – | – | – | – |